Li X, Li L
Heliyon. 2024; 10(20):e39044.
PMID: 39498064
PMC: 11532281.
DOI: 10.1016/j.heliyon.2024.e39044.
Li Z, Wang L, Zheng Q, Xu T, Yang K, Wang X
Cancer Rep (Hoboken). 2024; 7(6):e2103.
PMID: 39031740
PMC: 11190581.
DOI: 10.1002/cnr2.2103.
Almuqrin A, Alotaibi B, Aldali J, Alshalani A, AlSudais H, Aldali H
BMC Infect Dis. 2024; 24(1):576.
PMID: 38862891
PMC: 11167824.
DOI: 10.1186/s12879-024-09485-9.
Minakata D, Uchida T, Nakano A, Takase K, Tsukada N, Kosugi H
Int J Hematol. 2024; 119(2):183-195.
PMID: 38172385
PMC: 10830869.
DOI: 10.1007/s12185-023-03685-w.
Tsilingiris D, Vallianou N, Spyrou N, Kounatidis D, Christodoulatos G, Karampela I
Curr Obes Rep. 2023; 13(1):1-34.
PMID: 38159164
PMC: 10933194.
DOI: 10.1007/s13679-023-00542-z.
Single-center study of outcomes of patients with hairy cell leukemia who contracted SARS-CoV-2.
Annunzio K, Ozga M, Huang Y, Anghelina M, Bhat S, Blachly J
EJHaem. 2023; 4(4):1200-1202.
PMID: 38024604
PMC: 10660372.
DOI: 10.1002/jha2.764.
Recurrent COVID-19 Infection in a Refractory/Classical Hodgkin's Lymphoma Patient Undergoing Autologous Stem Cell Transplantation: A Case Report.
Hamed M, Alamoudi D
Cureus. 2023; 15(10):e46950.
PMID: 38022277
PMC: 10640764.
DOI: 10.7759/cureus.46950.
Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy.
Infante M, Nemirovsky D, Devlin S, DeWolf S, Tamari R, Dahi P
Transplant Cell Ther. 2023; 30(1):116.e1-116.e12.
PMID: 37806446
PMC: 11220618.
DOI: 10.1016/j.jtct.2023.09.027.
A Model-Based Cost-Effectiveness Analysis of Long-Acting Monoclonal Antibody (Tixagevimab and Cilgavimab: Evusheld) Preventive Treatment for High-Risk Populations Against SARS-CoV-2 in Korea.
Jo Y, Kim S, Jung J
J Korean Med Sci. 2023; 38(32):e250.
PMID: 37582500
PMC: 10427216.
DOI: 10.3346/jkms.2023.38.e250.
COVID-19 in hematological malignancies: Case series and literature review.
Ocheni S, Nwagha T, Amu N, Obodo O, Okereke K, Chikezie K
Ann Afr Med. 2023; 22(3):381-384.
PMID: 37417029
PMC: 10445697.
DOI: 10.4103/aam.aam_238_21.
COVID-19 in Adult Patients with Hematological Malignancies-Lessons Learned after Three Years of Pandemic.
Hus I, Szymczyk A, Manko J, Drozd-Sokolowska J
Biology (Basel). 2023; 12(4).
PMID: 37106746
PMC: 10136203.
DOI: 10.3390/biology12040545.
Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma.
Ishio T, Tsukamoto S, Yokoyama E, Izumiyama K, Saito M, Muraki H
Ann Hematol. 2023; 102(6):1421-1431.
PMID: 37041299
PMC: 10089694.
DOI: 10.1007/s00277-023-05204-7.
Cancer, more than a "COVID-19 co-morbidity".
Jani C, Schooley R, McKay R, Lippman S
Front Oncol. 2023; 13:1107384.
PMID: 36994197
PMC: 10040761.
DOI: 10.3389/fonc.2023.1107384.
Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates.
Ioannou P, Katsigiannis A, Papakitsou I, Kopidakis I, Makraki E, Milonas D
Viruses. 2023; 15(3).
PMID: 36992465
PMC: 10059055.
DOI: 10.3390/v15030756.
Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry.
Ljungman P, Tridello G, Pinana J, Ciceri F, Sengeloev H, Kulagin A
Front Immunol. 2023; 14:1125824.
PMID: 36960069
PMC: 10028143.
DOI: 10.3389/fimmu.2023.1125824.
Anticancer Therapy and Mortality of Adult Patients with Hematologic Malignancy and COVID-19: A Systematic Review and Meta-Analysis.
Lin W, Nguyen T, Wu L, Huang W, Su S
Life (Basel). 2023; 13(2).
PMID: 36836738
PMC: 9967921.
DOI: 10.3390/life13020381.
Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies.
Chien K, Peterson C, Young E, Chihara D, Manasanch E, Ramdial J
Blood Adv. 2023; 7(19):5691-5697.
PMID: 36696472
PMC: 9896882.
DOI: 10.1182/bloodadvances.2022008827.
Feasibility of Telemedicine in the Management Strategy of Patients With Lymphoma Amid the COVID-19 Pandemic in Spain: Prospective Observational Study.
Cordoba R, Lopez-Garcia A, Morillo D, Perez-Saenz M, Askari E, Prieto R
JMIR Form Res. 2023; 7:e34128.
PMID: 36645838
PMC: 10659072.
DOI: 10.2196/34128.
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA).
Infante M, Salmanton-Garcia J, Fernandez-Cruz A, Marchesi F, Jaksic O, Weinbergerova B
Front Oncol. 2022; 12:992137.
PMID: 36276116
PMC: 9583921.
DOI: 10.3389/fonc.2022.992137.
Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection.
Diamantopoulos P, Kontandreopoulou C, Stafylidis C, Vlachopoulou D, Giannakopoulou N, Vardaka M
Ann Hematol. 2022; 101(12):2711-2717.
PMID: 36271935
PMC: 9589533.
DOI: 10.1007/s00277-022-05003-6.
